| Literature DB >> 28406344 |
Doungdaw Chantasart1,2, Preeda Tocanitchart1, Amaraporn Wongrakpanich1,2, Veerawat Teeranachaideekul1,2, Varaporn Buraphacheep Junyaprasert1,2.
Abstract
The aims of this work were to develop and characterize the prolonged release piroxicam transdermal patch as a prototype to substitute oral formulations, to reduce side effects and improve patient compliance. The patches were composed of film formers (Eudragit®) as a matrix backbone, with PVC as a backing membrane and PEG200 used as a plasticizer. Results from X-ray diffraction patterns and Fourier transform-infrared spectroscopy indicated that loading piroxicam into films changed the drug crystallinity from needle to an amorphous or dissolved form. Piroxicam films were prepared using Eudragit® RL100 and Eudragit® RS100 as film formers at various ratios from 1:0 to 1:3. Films prepared solely by Eudragit® RL100 showed the toughest and softest film, while other formulations containing Eudragit® RS100 were hard and brittle. Drug release kinetic data from the films fitted with the Higuchi model, and the piroxicam release mechanism was diffusion controlled. Among all formulation tested, Eudragit® RL100 films showed the highest drug release rate and the highest drug permeation flux across human epidermal membrane. Increasing drug loading led to an increase in drug release rate. Eudragit® can be used as a film former for the fabrication of piroxicam films.Entities:
Keywords: Eudragit®; films; matrix dispersion; patch; piroxicam; transdermal
Mesh:
Substances:
Year: 2017 PMID: 28406344 DOI: 10.1080/10837450.2017.1319864
Source DB: PubMed Journal: Pharm Dev Technol ISSN: 1083-7450 Impact factor: 3.133